<DOC>
	<DOCNO>NCT00001037</DOCNO>
	<brief_summary>To determine safety immunogenicity 200 mcg MN rgp160 vaccine ( Immuno-AG ) versus placebo , administer two immunization schedule healthy volunteer . Per 06/15/94 amendment , determine safety immunogenicity 800 versus 200 mcg give fourth immunization 9 11 month third injection ( i.e. , month 17 ) . A gp160 vaccine develop IIIB strain HIV-1 find safe immunogenic healthy adult . Since MN strain HIV-1 representative large proportion HIV-1 isolates United States IIIB strain , evaluation gp160 vaccine derive MN strain important .</brief_summary>
	<brief_title>A Phase I , Multicenter , Clinical Trial Evaluate Safety Immunogenicity Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein ( rgp160 ) Human Immunodeficiency Virus Two Different Vaccination Schedules</brief_title>
	<detailed_description>A gp160 vaccine develop IIIB strain HIV-1 find safe immunogenic healthy adult . Since MN strain HIV-1 representative large proportion HIV-1 isolates United States IIIB strain , evaluation gp160 vaccine derive MN strain important . Volunteers randomize receive 200 mcg MN rgp160 placebo month 0 , 1 , 6 month 0 , 2 , 8 . For immunization schedule , ten volunteer receive vaccine two volunteer receive placebo . Per amendment , volunteer receive fourth immunization 800 200 mcg ( placebo ) 9 11 month third injection ( i.e. , month 17 ) follow 6 month afterward .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Normal history physical exam . Negative test HIV ELISA within 6 week prior immunization . CD4 count &gt; = 400 cells/mm3 . Normal urine dipstick esterase nitrate . No history immunodeficiency , chronic illness , autoimmune disease , use immunosuppresssive medication . Exclusion Criteria Coexisting Condition : Subjects follow condition exclude : Positive hepatitis B surface antigen . Medical psychiatric condition occupational responsibility preclude compliance . Active syphilis ( NOTE : If serology document false positive due remote ( &gt; 6 month ) infection , subject eligible ) . Active tuberculosis ( NOTE : Subjects positive PPD normal xray show evidence TB require INH therapy eligible ) . Subjects follow prior condition exclude : History anaphylaxis serious adverse reaction vaccine . Prior Medication : Excluded : Prior HIV vaccine . Live attenuate vaccine within past 60 day . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclude administer least 2 week prior HIV immunization . Experimental agent within past 30 day . Prior Treatment : Excluded : Blood product immunoglobulin within past 6 month . Higher risk behavior HIV infection determine screen questionnaire , include : History injection drug use within 12 month prior study entry . Higher intermediate risk sexual behavior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>